Holen Sie sich die Stockscreener-App
1.74
0.57%
-0.01
Vorhandelsmarkt:
1.74
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
77,722
Relative Volume:
0.36
Marktkapitalisierung:
$10.18M
Einnahmen:
$2.35M
Nettoeinkommen (Verlust:
$-2.56M
KGV:
-3.8831
EPS:
-0.4481
Netto-Cashflow:
-
1W Leistung:
-7.94%
1M Leistung:
-6.45%
6M Leistung:
-13.00%
1J Leistung:
-31.76%
1-Tages-Spanne:
$1.72
$1.78
1-Wochen-Bereich:
$1.60
$1.80
52-Wochen-Spanne:
$1.50
$2.87
Immuron Limited Adr Stock (IMRN) Company Profile
Firmenname
Immuron Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.74 | 9.74M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuron Limited Adr Aktie (IMRN) Neueste Nachrichten
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
Immuron Letter to Shareholders: Projects Update - GlobeNewswire Inc.
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewswire
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - FinancialContent
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
IMC Stock Price and Chart — ASX:IMC - TradingView
Finanzdaten der Immuron Limited Adr-Aktie (IMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):